<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231568</url>
  </required_header>
  <id_info>
    <org_study_id>113468</org_study_id>
    <nct_id>NCT01231568</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor</brief_title>
  <official_title>An Open-Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation-Positive Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the effects of a high fat meal on the pharmacokinetics of
      150 mg of GSK2118436, as well as the effects of particle size on the relative bioavailability
      of GSK2118436.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GSK2118436 is an orally administered, potent and selective small molecule BRAF inhibitor that
      is currently being developed for the treatment of BRAF mutation-positive tumors. This study
      is designed to evaluate the effects of particle size on the relative bioavailability of
      GSK2118436 (Cohort 1) and to evaluate the effects of a high-fat meal on the pharmacokinetics
      of GSK2118436 (Cohort 2). Subjects will randomly receive two of four possible regimens over
      two periods. Subjects enrolled in Cohort 1 will receive a single 150 mg dose of GSK2118436 as
      micronized particles fasted (gelatin capsule formulation) and a single 150 mg dose of
      GSK2118436 as non-micronized particles fasted (larger particle size). Subjects enrolled in
      Cohort 2 will receive a single 150 mg dose of GSK2118436 (HydroxyPropyl Methyl Cellulose
      (HPMC) capsule formulation) fasted and with a high-fat breakfast. GSK2118436 will be
      administered as the mesylate salt (equivalent to 150 mg free base). Safety and tolerability
      will also be evaluated. The study will be conducted at a sufficient number of centers to
      complete approximately 28 adult subjects (14 subjects per cohort) with BRAF mutation-positive
      tumors. Following completion of this study, subjects may continue dosing with GSK2118436 in
      the roll-over study, Protocol BRF114144.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2010</start_date>
  <completion_date type="Actual">May 13, 2011</completion_date>
  <primary_completion_date type="Actual">May 13, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma-concentration time curve (AUC) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC, Cmax, Tmax and t1/2 of GSK2118436 metabolites (GSK2285403, GSK2167542 and GSK2298683) and ratio of metabolite to parent drug GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>From date of first dose until transition to rollover protocol BRF114144 (approximately 12 days) or study follow up visit if subject does not transition to BRF114144 (approx 22 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen A</intervention_name>
    <description>Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted</description>
    <arm_group_label>Cohort 1 Treatment Sequence 2</arm_group_label>
    <arm_group_label>Cohort 1 Treatment Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen B</intervention_name>
    <description>Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted</description>
    <arm_group_label>Cohort 1 Treatment Sequence 2</arm_group_label>
    <arm_group_label>Cohort 1 Treatment Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen C</intervention_name>
    <description>Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted</description>
    <arm_group_label>Cohort 2 Treatment Sequence 1</arm_group_label>
    <arm_group_label>Cohort 2 Treatment Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen D</intervention_name>
    <description>Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal</description>
    <arm_group_label>Cohort 2 Treatment Sequence 1</arm_group_label>
    <arm_group_label>Cohort 2 Treatment Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age at the time of signing the informed consent
             form;

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form;

          -  Body weight &gt;/= to 45 kg and a Body Mass Index (BMI) &gt;/= to 19 kg/m2 and less than or
             equal to 35 kg/m2 (inclusive);

          -  Able to swallow and retain oral medication;

          -  BRAF mutation-positive tumor as determined via relevant genetic testing;

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at the time of
             transition to this study. NOTE: Subjects with an ECOG performance status of &lt;/= to 2
             may be eligible with the approval of the GlaxoSmithKline (GSK) Medical Monitor.

          -  Women of child-bearing potential and men with reproductive potential must be willing
             to practice acceptable methods of birth control. Additionally, women of child-bearing
             potential must have a negative serum pregnancy test within 14 days prior to the first
             dose of study treatment;

          -  Must have adequate organ function as defined by the following values:

          -  Absolute neutrophil count (ANC) &gt;/= to 1.2 x 10^9/L

          -  Hemoglobin &gt;/= to 9 g/dL

          -  Platelets &gt;/= to 100 x 10^9/L

          -  Serum bilirubin &lt;/= to 1.5 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;/= to 2.5 x ULN;
             &lt;5 x ULN if liver metastases are present (with approval of GSK medical monitor)

          -  Serum creatinine &lt;/= to ULN or calculated creatinine clearance &gt;/= 60 mL/min

          -  Prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin
             time (PTT) &lt; /= to 1.3 x ULN

          -  Left ventricular ejection fraction (LVEF) &gt;/= to institutional lower limit of normal
             by Echocardiogram

        Exclusion Criteria:

          -  Currently receiving cancer therapy (e.g., chemotherapy with delayed toxicity,
             extensive radiation therapy, immunotherapy, biologic therapy) within the last three
             weeks; chemotherapy regimens without delayed toxicity within the last two weeks; or
             use of an investigational anti-cancer drug within 28 days preceding the first dose of
             GSK2118436;

          -  Current use of a prohibited medication or requires any of these medications during the
             study;

          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from seven
             days prior to the first dose of study medication;

          -  Current use of therapeutic warfarin (note: low molecular weight heparin and
             prophylactic low-dose warfarin are permitted);

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia;

          -  Any major surgery within the last four weeks;

          -  Unresolved toxicity greater than National Cancer Institute Common Terminology Criteria
             for Adverse Events, version 4.0 (NCI CTCAE v4.0) [NCI, 2009] Grade 2 from previous
             anti-cancer therapy except alopecia;

          -  Presence of active gastrointestinal disease or other condition (e.g., small bowel or
             large bowel resection) that will interfere significantly with the absorption of drugs.
             If clarification is needed as to whether a condition will significantly affect
             absorption of drugs, contact the GSK medical monitor for permission to enroll the
             subject;

          -  A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or
             Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of HBV clearance
             may be enrolled with permission of the GSK medical monitor);

          -  Presence of invasive malignancy other than one of the malignancies covered under
             Inclusion Criterion #5; patients with a history of malignancy that have been
             definitively treated can be enrolled with approval of the GSK medical monitor;

          -  Subjects with brain metastases are excluded if their brain metastases are either:

        Symptomatic Treated (surgery, radiation therapy) but not clinically and radiographically
        stable one month after local therapy, or Asymptomatic and untreated but &gt; 1 cm in the
        longest dimension Patients with small (â‰¤ 1 cm in the longest dimension), asymptomatic brain
        metastases that do not need immediate local therapy can be enrolled with the approval of
        the GSK medical monitor. Subjects on a stable dose of corticosteroids for more than one
        month, or those who have been off corticosteroids for at least two weeks can be enrolled
        with approval of the GSK medical monitor. Subjects must also be off of enzyme-inducing
        anticonvulsants for more than four weeks;

          -  Presence of rheumatoid arthritis;

          -  History of alcohol or drug abuse within six months prior to screening;

          -  Corrected QT (QTc) interval &gt;/= to 480 msecs;

          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,
             or stenting within the past 24 weeks;

          -  Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)
             functional classification system; abnormal cardiac valve morphology documented by
             echocardiogram (subjects with minimal abnormalities [ie, mild regurgitation/stenosis]
             can be entered on study with approval from the GSK medical monitor); or history of
             known cardiac arrhythmias (except sinus arrhythmias) within the past 24 weeks;

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study drugs, or excipients (note: to date there are no known
             drugs chemically related to GSK2118436 which are approved by the Food and Drug
             Administration);

          -  Uncontrolled medical conditions (e.g., diabetes mellitus, hypertension),
             psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol; or unwillingness or inability to follow the procedures
             required in the protocol;

          -  Subjects with known glucose 6 phosphate dehydrogenase (G6PD) deficiency;

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, five half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer);

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period;

          -  Pregnant females as determined by positive human chorionic gonadotrophin (hCG) test at
             screening or prior to dosing;

          -  Lactating females who are actively breast feeding;

          -  Subject is mentally or legally incapacitated;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/113468?search=study&amp;study_ids=113468#rs</url>
    <description>Results for study 113468 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>food effect; high fat meal</keyword>
  <keyword>GSK2118436</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>particle size</keyword>
  <keyword>BRAF inhibitor</keyword>
  <keyword>BRAF positive tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

